Avalyn Pharma Statistics

Total Valuation

Avalyn Pharma has a market cap or net worth of $1.17 billion. The enterprise value is $1.04 billion.

Market Cap	1.17B
Enterprise Value	1.04B

Important Dates

The next estimated earnings date is Tuesday, June 2, 2026, after market close.

Earnings Date	Jun 2, 2026
Ex-Dividend Date	n/a

Share Statistics

Avalyn Pharma has 41.81 million shares outstanding.

Current Share Class	41.81M
Shares Outstanding	41.81M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	15.27%
Float	25.59M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	8.77
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 10.19, with a Debt / Equity ratio of 0.01.

Current Ratio	10.19
Quick Ratio	9.86
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -68.34% and return on invested capital (ROIC) is -45.46%.

Return on Equity (ROE)	-68.34%
Return on Assets (ROA)	-41.74%
Return on Invested Capital (ROIC)	-45.46%
Return on Capital Employed (ROCE)	-67.73%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	-$1.70M
Employee Count	50
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	44.30
Average Volume (20 Days)	794,732

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-91.29M
Pretax Income	-85.20M
Net Income	-85.20M
EBITDA	-91.25M
EBIT	-91.29M
Earnings Per Share (EPS)	-$4.56

Full Income Statement

Balance Sheet

The company has $138.41 million in cash and $1.67 million in debt, with a net cash position of $136.74 million or $3.27 per share.

Cash & Cash Equivalents	138.41M
Total Debt	1.67M
Net Cash	136.74M
Net Cash Per Share	$3.27
Equity (Book Value)	133.57M
Book Value Per Share	-10.11
Working Capital	129.47M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$81.48 million and capital expenditures -$344,000, giving a free cash flow of -$81.83 million.

Operating Cash Flow	-81.48M
Capital Expenditures	-344,000
Depreciation & Amortization	42,000
Net Borrowing	n/a
Free Cash Flow	-81.83M
FCF Per Share	-$1.96

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Avalyn Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-7.27%
FCF Yield	-6.98%

Analyst Forecast

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1